Alnylam Pharmaceuticals Stock Performance
| ALNY Stock | USD 253.74 0.39 0.15% |
The firm shows a Beta (market volatility) of 1.35, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Alnylam Pharmaceuticals will likely underperform. At this point, Alnylam Pharmaceuticals has a negative expected return of -0.0302%. Please make sure to confirm Alnylam Pharmaceuticals' standard deviation, potential upside, as well as the relationship between the Potential Upside and day median price , to decide if Alnylam Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Alnylam Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Alnylam Pharmaceuticals is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 0.15 | Five Day Return 1.94 | Year To Date Return 30.17 | Ten Year Return 152.35 | All Time Return 4.1 K |
1 | Disposition of 17560 shares by Pyott David E I of Alnylam Pharmaceuticals at 88.95 subject to Rule 16b-3 | 10/18/2024 |
2 | Alnylams Revenues Drop Sharply in Q3 | 10/31/2024 |
3 | Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update | 11/06/2024 |
4 | Exploring Three High Growth Tech Stocks For Dynamic Portfolios | 11/11/2024 |
5 | High Growth Tech Stocks To Watch In The Current Market | 11/14/2024 |
6 | Alnylam releases encouraging interim data on nucresiran for ATTR amyloidosis | 11/18/2024 |
7 | Alnylam Pharmaceuticals Receives Buy Rating from HC Wainwright | 11/19/2024 |
8 | High Growth Tech Stocks To Watch In None | 11/20/2024 |
9 | Acquisition by Kevin Fitzgerald of 3000 shares of Alnylam Pharmaceuticals subject to Rule 16b-3 | 11/25/2024 |
10 | Disposition of tradable shares by Kevin Fitzgerald of Alnylam Pharmaceuticals at 252.27 subject to Rule 16b-3 | 11/26/2024 |
| Begin Period Cash Flow | 868.6 M |
Alnylam |
Alnylam Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 26,269 in Alnylam Pharmaceuticals on August 30, 2024 and sell it today you would lose (895.00) from holding Alnylam Pharmaceuticals or give up 3.41% of portfolio value over 90 days. Alnylam Pharmaceuticals is currently does not generate positive expected returns and assumes 2.1905% risk (volatility on return distribution) over the 90 days horizon. In different words, 19% of stocks are less volatile than Alnylam, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Alnylam Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Alnylam Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Alnylam Pharmaceuticals, and traders can use it to determine the average amount a Alnylam Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0138
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ALNY |
Estimated Market Risk
| 2.19 actual daily | 19 81% of assets are more volatile |
Expected Return
| -0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Alnylam Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Alnylam Pharmaceuticals by adding Alnylam Pharmaceuticals to a well-diversified portfolio.
Alnylam Pharmaceuticals Fundamentals Growth
Alnylam Stock prices reflect investors' perceptions of the future prospects and financial health of Alnylam Pharmaceuticals, and Alnylam Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Alnylam Stock performance.
| Return On Equity | -15.01 | ||||
| Return On Asset | -0.0292 | ||||
| Profit Margin | (0.16) % | ||||
| Operating Margin | (0.15) % | ||||
| Current Valuation | 31.25 B | ||||
| Shares Outstanding | 128.98 M | ||||
| Price To Earning | (22.92) X | ||||
| Price To Book | 1,010 X | ||||
| Price To Sales | 15.62 X | ||||
| Revenue | 1.83 B | ||||
| Gross Profit | 868.6 M | ||||
| EBITDA | (258.24 M) | ||||
| Net Income | (440.24 M) | ||||
| Cash And Equivalents | 2.27 B | ||||
| Cash Per Share | 18.41 X | ||||
| Total Debt | 2.68 B | ||||
| Debt To Equity | 5.63 % | ||||
| Current Ratio | 3.48 X | ||||
| Book Value Per Share | 0.25 X | ||||
| Cash Flow From Operations | 104.16 M | ||||
| Earnings Per Share | (2.61) X | ||||
| Market Capitalization | 32.73 B | ||||
| Total Asset | 3.83 B | ||||
| Retained Earnings | (7.01 B) | ||||
| Working Capital | 2.01 B | ||||
| Current Asset | 1.11 B | ||||
| Current Liabilities | 62.1 M | ||||
About Alnylam Pharmaceuticals Performance
Evaluating Alnylam Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Alnylam Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Alnylam Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 104.82 | 99.58 | |
| Return On Tangible Assets | (0.14) | (0.15) | |
| Return On Capital Employed | (0.10) | (0.10) | |
| Return On Assets | (0.11) | (0.12) | |
| Return On Equity | 2.00 | 2.10 |
Things to note about Alnylam Pharmaceuticals performance evaluation
Checking the ongoing alerts about Alnylam Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Alnylam Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Alnylam Pharmaceuticals generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 1.83 B. Net Loss for the year was (440.24 M) with profit before overhead, payroll, taxes, and interest of 868.6 M. | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: Disposition of tradable shares by Kevin Fitzgerald of Alnylam Pharmaceuticals at 252.27 subject to Rule 16b-3 |
- Analyzing Alnylam Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Alnylam Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Alnylam Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Alnylam Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Alnylam Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Alnylam Pharmaceuticals' stock. These opinions can provide insight into Alnylam Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.